Aging interventions from older publications that deserve a new look

Why Read Old Papers?These days, from what I’m told by knowledgeable people, there’s a fairly tight feedback loop between current aging research and the biotech industry. When a new, major aging-related paper comes out, there are people seriously evaluating whether they can start a company around it.But that isn’t necessarily true when it comes to old research. There’s no…

Why NantKwest Stock Is Skyrocketing Today

Shares soar after the clinical-stage biotech releases exciting news. What happened After the company unveiled an exciting progress report at the J.P. Morgan Healthcare Conference, shares of NantKwest (NASDAQ:NK), a clinical-stage biotech that uses natural killer (NK) cells to fight cancer, surged 70% as of 11:19 a.m. EST on Thursday. So what NantKwest issued a press…

In One Chart: Last time this ‘clear danger sign’ flashed was in 1999, and we all know what happened next, fund manager warns

“When pigs squeal, feed them.” Brad Lamensdorf, portfolio manager for AdvisorShares Ranger Equity Bear ETF HDGE, -1.73%  , used that expression to describe what he sees in his “Chart of the Week,” which, he says, should give investors cause for concern. The chart, pulled from a recent Wall Street Journal story, essentially shows how much…

Legendary Biotech Pioneer Fires a Shot Across Healthcare Industry’s Bottom Line

Meet EQRx, a biotech startup founded by an industry legend who wants to develop new therapies sold at generic prices, undermining the drug industry’s profits. Alexis Borisy, one of the biopharmaceutical industry’s most successful entrepreneurs, recently raised $200 million to launch a new company called EQRx. While the amount raised isn’t unusual, the mission driving…

Why Nektar Therapeutics Stock Is Sinking Today

The biotech is throwing in the towel on an experimental painkiller after receiving a thumbs-down from two FDA advisory committees. What happened Shares of Nektar Therapeutics (NASDAQ:NKTR) had sunk 15.1% lower as of 11:06 a.m. EST on Wednesday. The decline came after two U.S. Food and Drug Administration (FDA) advisory committees voted unanimously to not…

TC Top Picks: Veamly

TC Video 2 weeks Veamly centralizes all your work in one place, bringing all your collaboration apps in one desktop app and all your conversations in a main feed. The TC Top Picks program showcases outstanding early-stage startups across these categories: AI/Machine Learning, Biotech/Healthtech, Blockchain, Fintech, Mobility, Privacy/Security, Retail/E-commerce,